Document Detail


Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment.
MedLine Citation:
PMID:  17873308     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Approximately 60% of anaemic cancer patients respond to epoetin treatment. An early marker of response would be valuable in order to avoid ineffective treatment. We have previously shown that beta globin mRNA increases rapidly after epoetin beta treatment of healthy controls. In the present study we have evaluated whether a change of this marker during the first 2 weeks of epoetin treatment could predict later Hb response in anaemic cancer patients. Twenty cancer patients with Hb <11 g/dl received epoetin beta (NeoRecormon) 10,000 IU three times weekly during 6 weeks. Hb, reticulocytes and beta-globin mRNA were followed. The latter was measured quantitatively using PCR via the 5' nuclease assay. Eleven patients responded with a Hb increase of >1 g/dl, nine were nonresponders. All responders increased in beta-globin mRNA within 2 weeks, mean 7.7 x base-line. With a cut-off of an increase of 3 x base-line value, we obtained a specificity of 45% and a sensitivity of 91% for the prediction of a later increase of Hb >1 g/dl. With a cut-off of 4x base-line, the specificity increased to 66%, but the sensitivity decreased to 82%. Beta globin mRNA increases before Hb in all responding patients. However, some non-responding patients also show an increase, and there is a trade-off between specificity and sensitivity as the cut-off level is set at different levels. Compared to reticulocyte count, beta-globin mRNA is more reliable in the individual patient, but the clinical usefulness of the assay needs to be evaluated in further studies.
Authors:
Gunnar Birgegård; Fredrik Dahl; Bengt Glimelius; Ulf Landegren
Related Documents :
6361748 - Transfusion-induced anergy: skin test as an index for pretransplant transfusions.
7296148 - Dupuytren's disease and the sickle-cell trait in a female black patient.
3422548 - Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (aids...
9484118 - Homozygous beta thalassemia in an african-american pediatric patient.
6363798 - A controlled study of the effect of indomethacin in uremic pericarditis.
14636658 - Driving disability and dizziness.
Publication Detail:
Type:  Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Medical oncology (Northwood, London, England)     Volume:  24     ISSN:  1357-0560     ISO Abbreviation:  Med. Oncol.     Publication Date:  2007  
Date Detail:
Created Date:  2007-09-17     Completed Date:  2008-01-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435512     Medline TA:  Med Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  318-22     Citation Subset:  IM    
Affiliation:
Department of Haematology, University Hospital, Uppsala 751 85, Sweden. gunnar.birgegard@medsci.uu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia / drug therapy*,  etiology
Beta-Globulins / drug effects*,  genetics
Biological Markers / analysis
Cell Count
Erythropoietin, Recombinant / therapeutic use*
Hematinics / therapeutic use*
Hemoglobins / drug effects*
Humans
Neoplasms / complications
RNA, Messenger / analysis
Reticulocytes / cytology
Sensitivity and Specificity
Treatment Outcome
Chemical
Reg. No./Substance:
0/Beta-Globulins; 0/Biological Markers; 0/Erythropoietin, Recombinant; 0/Hematinics; 0/Hemoglobins; 0/RNA, Messenger; 0/epoetin beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical stage-depending decrease of NK cell activity in multiple myeloma patients.
Next Document:  Anaemia in patients with cancer: role of inflammatory activity on iron metabolism and severity of an...